Sanofi AI Drug Discovery Deal Bolsters Baidu-Backed Startup BioMap

But Field Faces Data, Other Challenges

As artificial intelligence-aided drug discovery gains momentum, Sanofi appears keen to hop onboard via a recent tie-up with leading Chinese AI company BioMap. But data challenges, a hard-to-define value proposition, concerns over data security and looming regulations are making others hesitant.

Two Years Of Artificial Intelligence Deals: A Pharma Snapshot
Sanofi taps Baidu-backed BioMap to speed up AI-powered drug discovery • Source: Shutterstock: By GeoArt

In a deal signed on the sidelines of the China International Import Exhibition held in Shanghai over 6-10 November, Sanofi has teamed up with Chinese artificial intelligence drug discovery firm BioMap to enhance its R&D efforts.

Still in its infancy, AI-powered drug discovery has great promise but little practical validation so far, but the new alliance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By 

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

More from Focus On Asia

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By 

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis